Combination Lipid-Lowering Therapy Linked to Greater Drop in LDL-C
By Elana Gotkine HealthDay Reporter
FRIDAY, March 28, 2025 -- Combination lipid-lowering therapy (LLT) is associated with a greater reduction in low-density lipoprotein cholesterol (LDL-C) compared with statin monotherapy, according to a study published online March 23 in the Mayo Clinic Proceedings.
Maciej Banach, M.D., Ph.D., from the Medical University of Lodz in Poland, and colleagues conducted a systematic literature review of 14 studies (11 randomized controlled trials and three cohort studies) with 108,373 very high-risk patients to examine the efficacy of combination LLT compared to statin monotherapy for LDL-C reduction, associated adverse events, and outcomes.
The researchers found that compared with statin monotherapy, combination LLT significantly more effectively reduced the LDL-C level from baseline in a pooled analysis (mean difference, –12.96 mg/dL) and significantly reduced all-cause mortality, major adverse cardiovascular events, and stroke incidence (odds ratios, 0.81, 0.82, and 0.83, respectively); the effect on cardiovascular mortality was not significant. The groups had a comparable risk for adverse events and therapy discontinuation rates.
"Combination LLT should be considered at the outset of therapy initiation to maximize LDL-C goal attainment and improve reduction in hard cardiovascular disease end points," the authors write. "These issues should be emphasized more emphatically by guidelines."
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Early Combination of Lipid-Lowering Therapy Beneficial After Myocardial Infarction
MONDAY, April 28, 2025 -- For patients with myocardial infarction (MI), early oral combination lipid-lowering therapy (LLT) is beneficial, according to a study published online in...
Olpasiran Leads to Significant Reduction in Oxidized Phospholipids
FRIDAY, Feb. 21, 2025 -- Olpasiran, a small interfering RNA, which blocks lipoprotein(a) (Lp[a]) production, leads to a significant and sustained reduction in oxidized...
Elevated HDL Cholesterol Linked to Increased Risk for Glaucoma
WEDNESDAY, Feb. 5, 2025 -- Elevated high-density lipoprotein cholesterol (HDL-C) is associated with an increased risk for glaucoma, while elevated low-density lipoprotein...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.